Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHYTHM: ARNI Effect on Ventricular Arrhythmia in HFrEF
NCT04491136Phase 4Terminated
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Primary endpoints: Proportion of Paired Patients With Ventricular Arrhythmia (VA) Events at 12 months and Proportion of Paired Patients Who Experienced at Least One ICD or CRT-D Shock and ATP Event at 12 months. Started Nov 2020; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04491136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491136.